Evidence map›Paper›PMID 42377389›Full record

ArticleCancer immunology research2026

Multinucleated Giant Cells in Human Pancreatic Cancer Are a Distinct Macrophage Population Undergoing a DNA Damage Response and Associated with an Aggressive Tumor Microenvironment.

Marika Viatore, Rebecca Polidori, Anna Rita Putignano, Arturo Bonometti, Daoud Rahal, Marialuisa Barbagallo, Lisa Veghini, Greta Donisi, Gianluca Basso, Desirée Giuliano and 14 more

Abstract read
In one paragraph

Article in Cancer immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Marika Viatore *Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.ORCID 0000-0001-9554-6468
Rebecca Polidori *Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.ORCID 0000-0003-3016-7613
Anna Rita Putignano *Department of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-6462-9188
Arturo BonomettiDepartment of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-3258-0727
Daoud RahalDepartment of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-5579-7550
Marialuisa BarbagalloDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-0294-2299
Lisa VeghiniDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.ORCID 0000-0003-3289-1189
Greta DonisiDepartment of Biomedical Science, Humanitas University, Milan, Italy.ORCID 0000-0002-5873-6577
Gianluca BassoHumanitas Genomic Facility, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-8430-4727
Desirée GiulianoHumanitas Genomic Facility, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-0576-4125
Sergio MarchiniHumanitas Genomic Facility, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-1783-7651
Marco ErreniDepartment of Biomedical Science, Humanitas University, Milan, Italy.ORCID 0000-0002-1922-0818
Maria Rita FumagalliUnit of Advanced Optical Microscopy, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-3404-5779
Fabio PasqualiniDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-4852-3794
Fabio GrizziDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-0925-742X
Paola SpaggiariDepartment of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0003-2905-1736
Silvia UccellaDepartment of Pathology, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-5714-7295
Silvia BozzarelliMedical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0002-8118-7342
Alessandro ZerbiDepartment of Biomedical Science, Humanitas University, Milan, Italy.ORCID 0000-0002-9176-0448
Giovanni Luigi CaprettiDepartment of Biomedical Science, Humanitas University, Milan, Italy.ORCID 0000-0001-9429-3008
Vincenzo CorboDepartment of Engineering for Innovation Medicine, University of Verona, Verona, Italy.ORCID 0000-0002-6340-8009
Massimo LocatiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.ORCID 0000-0003-3077-590X
Alberto MantovaniDepartment of Immunology and Inflammation, IRCCS Humanitas Research Hospital, Milan, Italy.ORCID 0000-0001-5578-236X
Federica MarchesiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.ORCID 0000-0002-7212-5721

Funding

Federica Marchesi AIRC IG 2025 - ID. 31899
6 · The paper itself

Abstract

Macrophages (Mϕ) constitute a dominant and functionally diverse immune population within the microenvironment of pancreatic ductal adenocarcinoma (PDAC), yet how Mϕ heterogeneity contributes to the tumor remains poorly defined. In an institutional cohort of 145 PDAC specimens, we identified a population of multinucleated giant cells (MGC) of Mϕ origin, an entity previously described in chronic inflammation but rarely in cancer. CD68+ MGCs were present in 28% of tumors, enriched in squamous, nonglandular regions, and more frequent after neoadjuvant chemotherapy. By integrating spatial transcriptomics and quantitative imaging, we defined the features of these cells, which, compared with MGCs in nonneoplastic inflammatory lesions, lacked canonical polarization markers (HLA-DR and CD163) and displayed a distinctive transcriptional program characterized by upregulation of the POLR2K, TUBA8, COX5B, and VDAC1 genes, which encode proteins involved in DNA repair, oxidative stress, and MYC signaling. Spatial analyses revealed activation of hypoxia and extracellular matrix-remodeling pathways in MGC-associated niches, and experimental hypoxia promoted MGC formation in vitro. Consistent with these data, we found that in the The Cancer Genome Atlas (TCGA) Pancreatic Adenocarcinoma (PAAD) dataset a Mϕ MGC gene signature was enriched in the squamous PDAC subtype and correlated with poorer overall survival (P = 0.018). Morphometric and immunofluorescence analyses further showed increased 53BP1+Ki67+ nuclei and nuclear atypia in MGCs, indicating ongoing proliferation despite DNA damage. Together, these data identify MGCs of Mϕ origin as an immune cell state shaped by hypoxia and stress signaling, associated with aggressive tumor phenotypes, and potentially exploitable as an immune classifier in PDAC.

Indexed as

Carcinoma, Pancreatic DuctalDNA DamageGiant CellsMacrophagesPancreatic NeoplasmsTumor MicroenvironmentFemaleHumansMale

Identifiers

PMID42377389
PMCPMC13535325

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.